MarketPulse

bispecific antibody

9 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Mestag's MST-0312 Advances to AACR Stage Ahead of Mid-2026 Clinical Launch

Mestag Therapeutics' FAP-targeted bispecific antibody MST-0312 selected for late-breaking AACR presentation in April 2026, with Phase 1 trials expected to begin mid-year.
JNJMRKsolid tumorsbispecific antibody
BenzingaBenzinga··Vandana Singh

Sanofi's Dual-Action Drug Shows Promise Beyond Lungs in Asthma, Polyp Trials

Sanofi's lunsekimig met primary endpoints in asthma and nasal polyp trials but failed dermatitis goals, showing favorable safety across all studies.
SNYUPBREGNGSKatopic dermatitisPhase 2 trials
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi

Sanofi's Lunsekimig Clears Key Phase 2 Hurdles in Asthma and Sinus Disease

Sanofi's bispecific antibody lunsekimig met primary endpoints in phase 2 asthma and chronic rhinosinusitis studies, though atopic dermatitis trial missed targets.
SNYchronic rhinosinusitis with nasal polypsatopic dermatitis
BenzingaBenzinga··Bamboo Works

Keymed's $320M Windfall: Chinese Biotech Scores Major Exit via Gilead Acquisition

Keymed Biosciences receives up to $320M from Gilead's acquisition of its immunotherapy spinoff Ouro Medicines, marking a landmark exit for Chinese biotech.
AZNGILDacquisitionautoimmune disease
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Celldex Raises $300M to Fuel Barzolvolimab Launch and Pipeline Expansion

Celldex prices $300M stock offering at $29/share to fund commercial launch of CSU treatment and expand bispecific antibody platform.
CLDXbarzolvolimabclinical development
GlobeNewswire Inc.GlobeNewswire Inc.··Mestag Therapeutics

Mestag Therapeutics Secures $40M to Advance FAP-Targeted Cancer Immunotherapy

Mestag Therapeutics closes $40M financing and appoints leadership to advance FAP-targeted cancer immunotherapy MST-0312 into Phase 1 clinical trials.
JNJclinical trialbispecific antibody
GlobeNewswire Inc.GlobeNewswire Inc.··Johnson & Johnson

J&J Seeks EMA Approval for TECVAYLI as First-Line Monotherapy in Multiple Myeloma

Johnson & Johnson submits EMA application for TECVAYLI monotherapy in relapsed/refractory multiple myeloma, citing 71% risk reduction in disease progression or death versus standard care.
JNJEMA approvalPhase 3 trial
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Aclaris Advances Dual-Target Antibody into Asthma Study Following Dermatitis Trial Launch

Aclaris launches Phase 1b asthma trial for ATI-052, a dual-target antibody also in dermatitis trials. Results expected mid-2026.
ACRSclinical developmentatopic dermatitis
GlobeNewswire Inc.GlobeNewswire Inc.··Macrogenics, Inc.

MacroGenics Halts New Patient Enrollment in LINNET Trial Following FDA Clinical Hold

FDA places partial clinical hold on MacroGenics' LINNET trial due to serious adverse events including thrombocytopenia, myocarditis, and one death. New enrollment halted.
MGNXFDA clinical holdbispecific antibody